Novel Drug, NFX-179, Inhibits MEK Activity, Prevents Cutaneous Squamous Cell Carcinoma Development
Moffitt Cancer CenterIn a new article published today in Science Translational Medicine, a team of Moffitt Cancer Center researchers, in collaboration with NFlection Therapeutics and researchers at Stanford University, reports the identification of a new drug, NFX-179, that can be applied to the skin and was shown to prevent the development of cutaneous squamous cell carcinoma in pre-clinical models.